Follicle-Stimulating Hormone Receptor Expression and Its Potential Application for Theranostics in Subtypes of Ovarian Tumors: A Systematic Review
Open Access
Abstract
Ovarian cancer mortality rates have not decreased significantly in the past years. As most women are still diagnosed in an advanced stage, there is a need for new treatment strategies for recurrent disease. A potentially new developing targeted approach, theranostics, combines diagnostics and treatment using radiopharmaceuticals. Through target receptors, imaging and treatment of malignant tissue can be achieved. For ovarian malignancy, the follicle-stimulating hormone (FSH) receptor may serve as a possible target since expression appears to be limited to ovarian cells. In this systematic review, we aim to gather all available literature on the expression of the FSH receptor in ovarian tumors. Pubmed, Embase and the Cochrane databases were searched until December 2023 for eligible studies. The search yielded 41 studies, mostly regarding serous carcinomas, sex cord–stromal tumors (SCSTs) and cell lines of serous and SCSTs. Various techniques were used to analyze the expression of the FSH receptor. For serous carcinomas, conflicting results on the expression of the FSH receptor were found. Studies on SCSTs, mainly studying the subtype of granulosa cell tumors, all showed positive expression of the FSH receptor. In the cell lines studies, the KGN cell line derived from a granulosa cell tumor shows positive expression in all studies. Available studies show that SCSTs express the FSH receptor. A theranostic approach targeting the FSH receptor may, therefore, provide a useful new approach for this malignancy with limited therapeutic options in recurrent disease.Keywords
This publication has 61 references indexed in Scilit:
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumorsPathology - Research and Practice, 2018
- Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?Molecular Diagnosis & Therapy, 2016
- Pathology of cancers of the female genital tractInternational Journal of Gynecology & Obstetrics, 2015
- Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapyGynecologic Oncology, 2014
- Follicle stimulating hormone‐induced growth promotion and gene expression profiles on ovarian surface epithelial cellsInternational Journal of Cancer, 2004
- Quantitative analysis of follicle‐stimulating hormone receptor in ovarian epithelial tumors: A novel approach to explain the field effect of ovarian cancer development in secondary mullerian systemsInternational Journal of Cancer, 2002
- Loss of Alternately Spliced Messenger RNA of the Luteinizing Hormone Receptor and Stability of the Follicle-Stimulating Hormone Receptor Messenger RNA in Granulosa Cell Tumors of the Human OvaryGynecologic Oncology, 2000
- Ovarian Epithelial Tumor Growth Promotion by Follicle-Stimulating Hormone and Inhibition of the Effect by Luteinizing HormoneGynecologic Oncology, 2000
- Localization of gonadotropin binding sites in human ovarian neoplasmsAmerican Journal of Obstetrics and Gynecology, 1989